2006 was a busy year for merger and acquisition (M&A) activity in the pharmaceutical services industry, and all signs point
to 2007 being at least as active. The resulting consolidation and changes in ownership are altering the face of the industry.
PharmSource counted almost 60 deals completed in 2006, with a total value of nearly $2 billion. The deal sizes range from the $2 million
that Canadian contract laboratory company Warnex (Montreal, Canada) paid for the Blainville, Quebec analytical operations of MDS Pharma Services (Montreal, Canada) to the $567 million that a consortium of private-equity firms is paying for pharmaceutical chemical manufacturer
Groupe Novasep (Pompey, France). The number of deals was almost equally divided between clinical and nonclinical development and manufacturing
One deal alone promises to make 2007 an even bigger year than 2006: Cardinal Health's (Dublin, Ohio) Pharmaceutical Technologies and Services (PTS) business, which Cardinal Health announced it intends to divest
by mid-year, is expected to bring nearly $2 billion on its own. The industry also is waiting to learn whether the board of
directors of dose manufacturer Patheon (Toronto, Canada) decides to sell all or part of its operations. If it does, assets worth hundreds of millions of dollars
could change hands. Add to those two events the normal flow of small, tactical deals and the likelihood of a surprise announcement
or two, and 2007 should be quite a year for investment bankers representing contract-services clients.
Even if the Cardinal Health and Patheon transactions were not looming over the industry, 2007 would probably be a busy year
because the factors that drove contract services M&A activity in 2006 are still very much in place: a set of compelling business
rationales and readily available financing.
The business rationales for deal-making reflect market trends in the pharmaceutical services industry.
Private-equity firms that own contract research organizations (CROs) and contract manufacturing organizations (CMOs)
Early-development boom. The number of early-stage candidates in the drug development pipeline has grown markedly this decade—Phase I candidates are
up 50% according to data from IMS, Inc.—and service providers want to make sure they have the capacity to serve them. Companies
that support the development of early-stage compounds, including Phase I research, formulation, and analytical services, have
been in strong demand by acquirers.
Demand for Phase I beds has far outstripped the supply, making Phase I capacity a hot commodity in 2006. Covance (Princeton, NJ) added 11 sites and 500 beds to its network with its acquisition of the Radiant Research Phase I facilities. PRA International (Reston, VA) gained a Phase I foothold in Europe with its acquisition of Pharma Bio-Research, adding to its existing facility in Lenexa, Kansas. SGS (Geneva, Switzerland) bought a major Phase I presence with its acquisition of aster.cephac early in 2006.